EGFR and colorectal cancer: Already in other known targetable mutations discussed above, such as EGFR in colorectal cancer or BCR-ABL1 in CML, the use of next generation sequencing (NGS) has proved invaluable in identifying not only actionable mutations, but also for screening “gatekeeper” mutations that may confer resistance to therapy.